Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Low-risk gestational trophoblastic neoplasia (FIGO score 0 to 6), drawn from the whole corpus: 1 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
Methotrexate and actinomycin D have never been compared head to head with the regimens most centres use.
Which resistant patients should receive immunotherapy rather than EMA-CO is not settled.
Overtreatment of quiescent disease with persistently low hCG is a risk.
Care is centralised in only a few countries.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
hCG normalisation in 8 of 15 women (53 percent) with single-agent chemotherapy-resistant disease, none of whom relapsed; grade 1 to 2 adverse events in 93 percent and no treatment-related grade 3 events.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.
A milestone in how this cancer is treated.